Peptides for Endurance: What the Evidence Shows (2026)

No peptide sold for endurance has a published, controlled human trial showing that it makes a trained person faster, raises their VO2max, or extends time to exhaustion. That is the whole answer, and everything below is the reasoning behind it: which compounds exist, what tier of evidence each one actually sits on, which are outright banned in tested sport, and what the honest levers are for an athlete who wants a bigger aerobic engine.

The compounds sold against this goal fall into five groups. MOTS-c has the strongest data in the set — real, striking, and in rodents. SS-31 (elamipretide) has been through genuine clinical trials, but in mitochondrial disease rather than sport, and its largest one missed. 5-amino-1MQ is an oral compound whose reasoning chain is a step longer than the injectables. AICAR is the original "exercise in a pill" molecule and it is prohibited and monitored in athlete urine. And EPO-adjacent peptides are not a gray area at all — they are doping, and the best randomized trial of erythropoietin in trained cyclists found race times unchanged¹¹.

MOTS-c — the strongest endurance data in the category, and it is in mice

MOTS-c is the compound this question usually starts with, and it deserves the fair hearing our full review gives it in MOTS-c and endurance.

The rodent work is genuinely impressive. The landmark 2021 study established MOTS-c as an exercise-induced, mitochondrially encoded regulator of age-dependent physical decline, and showed that injecting it improved physical capacity and running performance in mice, with the effect most pronounced in aged animals¹. A separate experiment gave a single 15 mg/kg dose to untrained mice and measured a 12% increase in total running time and a 15% increase in distance on an acute exercise test, alongside evidence that four to eight weeks of voluntary running raised MOTS-c protein in rodent muscle by roughly 1.5- to 5-fold².

Now the human side, which is where the pitch comes apart. The human literature is observational, and two findings cut directly against the marketing. A preliminary human study found that serum MOTS-c concentration correlated with lower-body muscle strength and was explicitly not related to maximal oxygen uptake³ — VO2max being the closest thing physiology has to a hard endurance number. And in the training literature the arrow runs the other way: endurance training enhances skeletal-muscle mitochondrial respiration by promoting MOTS-c secretion⁴. Training raises the peptide. That is a fact about what your body does when you train, not evidence that the peptide substitutes for training.

There is no controlled human trial in which people were given MOTS-c and shown to gain endurance. Anti-doping science, meanwhile, has already moved: a validated mass-spectrometry assay for MOTS-c in plasma, built to the World Anti-Doping Agency's laboratory standard, was published in 2019⁵. A detection method exists because the misuse was anticipated.

SS-31 / elamipretide — real clinical trials, none of them in sport

Elamipretide is the most seriously developed molecule in this group, and the contrast with MOTS-c is instructive. It binds cardiolipin in the inner mitochondrial membrane, and the preclinical work is specific: in aged mouse muscle it improved mitochondrial ADP sensitivity through the adenine nucleotide translocator and rescued muscle force and cardiac systolic function⁷. If mitochondrial mechanism translated into human performance anywhere, this is where you would expect to see it.

It was tested. MMPOWER-3 was a Phase 3, randomized, double-blind, placebo-controlled trial over 24 weeks in adults with primary mitochondrial myopathy — a genuine disease of the mitochondria, and the most favorable population imaginable for the mechanism. It did not meet its primary endpoints⁶. Our full read of the program, including the earlier trials that looked more promising, is in SS-31 (elamipretide): the mitochondrial evidence.

Sit with what that implies for a healthy athlete. The most rigorous test of a mitochondria-targeted peptide, in the population most likely to respond, at a sponsor-chosen dose and duration, did not produce the result. A vendor selling the same molecule to a marathoner is selling a step the drug development program did not earn.

5-amino-1MQ — an oral story with one more link to hold

5-amino-1MQ inhibits nicotinamide N-methyltransferase (NNMT). The foundational evidence is a 2014 Nature paper in which NNMT knockdown protected mice against diet-induced obesity⁸ — a knockdown experiment in rodents, not a study of the oral compound in athletes.

The reasoning chain sold to endurance readers runs: inhibit the enzyme, raise NAD+, improve mitochondrial function, ride longer. Each link has to hold, and the last one has never been tested in a human trial with a performance endpoint. We take the compound apart against MOTS-c in 5-amino-1MQ vs MOTS-c and on its own terms in 5-amino-1MQ: the evidence.

Is AICAR really "exercise in a pill"?

The phrase comes from one paper, and it is worth reading precisely. In 2008, researchers reported that four weeks of AICAR treatment in sedentary mice induced metabolic genes and enhanced running endurance by 44%, and that a PPAR-delta agonist plus training synergistically increased oxidative muscle fibers⁹. The paper is titled, plainly, "AMPK and PPARdelta agonists are exercise mimetics." That single mouse result is the entire origin of the folklore.

What happened next matters more than the headline. AICAR is prohibited in sport, and anti-doping laboratories have had to work out how to interpret it, because low concentrations occur naturally in human urine. A survey of 12,377 athlete samples found a mean urinary AICAR concentration of 647 ng/mL with a 99th percentile at 1,786 ng/mL, and the authors proposed that any sample above roughly 2,000 to 2,500 ng/mL go to carbon isotope ratio mass spectrometry to establish whether the origin is endogenous or administered¹⁰. Athletes are being screened for this compound with published thresholds. There is no controlled human trial showing AICAR improves endurance performance, and there is a functioning detection pathway for anyone who tries.

EPO-adjacent peptides — this one is not ambiguous

Peptide-based erythropoietin-receptor agonists and EPO mimetics are marketed at the edges of the same gray market. There is no evidence question to weigh here: these sit squarely in the prohibited peptide-hormone class, year-round, and a prescription does not change that. The 2026 list added pegmolesatide as a named example of an EPO mimetic, which we cover in what the 2026 WADA list changed for peptides.

The performance irony is worth stating. In a double-blind, randomized, placebo-controlled trial, 48 well-trained cyclists received recombinant human erythropoietin or placebo for eight weeks. Hemoglobin, maximal power output and VO2max all rose in the treated group — and submaximal performance and the actual road race to the Mont Ventoux summit did not differ between groups¹¹. The laboratory number moved; the race did not.

Do GLP-1 drugs help or hurt an endurance athlete?

This is now the most common version of the question we get, because the drugs are everywhere and endurance sport rewards a lower body mass.

The tradeoff is measurable. A 2026 systematic review and meta-analysis of 20 randomized trials covering 15,782 participants found that lean mass made up 25% to 39% of total weight lost on incretin therapy — 35.2% with semaglutide, 25.4% with tirzepatide, 26.8% with liraglutide — with lifestyle intervention at a comparable 26.2%, and lifestyle plus resistance training producing the most favorable profile at 17.5%¹². For a cyclist or a runner, losing a quarter to a third of the weight as lean tissue is a direct hit to the machinery that produces power. We cover the body-composition picture in semaglutide and tirzepatide muscle loss and the athlete-specific version in retatrutide, athletes and body recomposition.

The practical reading: these are metabolic medications with a real indication, not endurance aids, and the muscle question is one to raise with the clinician prescribing them rather than settle from a forum thread.

Where does each of these stand in tested sport?

Short version: the ones with any performance story attached are prohibited, and the catch-all classes do most of the work. The peptide-hormone class is non-exhaustive, so a compound does not need to be named to be covered, and unapproved research substances are captured separately. Per-compound answers are in our prohibited-substance checker, the year's changes are in the 2026 WADA list, and what a standard panel does and does not look for is in do peptides show up on drug tests.

Can you trust what is in the vial?

Separate from efficacy, and often the larger practical risk. MOTS-c, 5-amino-1MQ and AICAR reach consumers mainly as research chemicals, where identity, purity, dose and sterility are asserted rather than demonstrated. Read the certificate of analysis properly before you read the sales page — our walkthrough is how to verify a peptide COA, with the pattern-matching guide in peptide vendor red flags and the legal picture in where to buy peptides and research-chemical legality. Regulatory movement on individual compounds, including the narrow MOTS-c advisory vote that vendors quote out of context, is tracked in the peptide regulatory tracker and unpacked in MOTS-c FDA status.

What actually builds endurance (the proven levers)

The uncomfortable part of writing this page honestly is that the interventions with real human evidence are cheap, legal and unglamorous.

Structured training is the non-negotiable driver, and nothing below replaces it. On top of it, altitude has the best-supported adjunct evidence: a meta-analysis of 51 studies found that live-high train-low protocols substantially enhanced maximal endurance power output in subelite athletes, with natural live-high train-low the best-performing protocol in elite athletes — while also identifying substantial placebo and training-camp effects mixed into some results¹³. Dietary nitrate has a 2025 umbrella review of 20 meta-analyses behind it, covering 180 primary studies: it improved time-to-exhaustion tasks, total distance covered, muscular endurance and peak power output, with larger effects at 6 mmol per day or more taken for more than three days, and no significant effect on several other outcomes¹⁴. And caffeine has 21 published meta-analyses summarized in a single umbrella review of moderate-to-high methodological quality¹⁵.

Three legal interventions, each with a synthesis of dozens of human trials behind it. Set that against a category where the flagship compound's endurance evidence is a mouse treadmill.

Bottom Line

Sort the endurance peptides by evidence and the ranking is short. MOTS-c has striking rodent data¹² and human data that runs the wrong way — uncorrelated with VO2max³, and raised by training rather than raising it⁴. Elamipretide had the best shot and its Phase 3 trial did not meet its primary endpoints⁶. 5-amino-1MQ rests on a rodent knockdown study⁸. AICAR's reputation is one mouse paper⁹ and its practical reality is a urine threshold¹⁰. EPO-adjacent peptides are doping, and even real EPO left race times unchanged in a controlled trial¹¹.

None of that means these molecules are inert; MOTS-c biology in particular is real and worth studying. It means the specific claim — that injecting one of them makes a human being go longer — has not been tested and passed, in any of them. For the adjacent questions, see peptides for energy, peptides for muscle growth, peptides for recovery and healing, peptides vs SARMs, thymosin alpha-1 and athlete immunity, and the graded map in what are peptides good for.

On price, the endurance compounds are among the most expensively packaged items on the telehealth desks we check. ElitePhysiqMD prices MOTS-C at $337.50 a month, the dearest of eighteen individually priced peptides on a page whose homepage advertises peptide therapy "from $161/mo". Live Vital advertises MOTS-c at $149/mo on a bench where several "/mo" figures still come from ten-week protocols divided by three — its CJC-1295/ipamorelin "$116/mo" is $349 for ten weeks, which is about $152 a calendar month. Verified per-provider numbers are on the best recovery peptide providers ranking and in the price transparency index, as of August 2026.

This article is educational and is not medical advice. Anything involving an injection, a prescription or a competitive license belongs in a conversation with a clinician who knows your history.